Nautilus Biotechnology Stock Analysis

Nautilus Stock Analysis Notes

About 34.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.16. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nautilus Biotechnology recorded a loss per share of 0.54. The entity had not issued any dividends in recent years. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Nautilus Biotechnology contact Sujal Patel at 206 333 2001 or learn more at https://www.nautilus.bio.

Nautilus Biotechnology Investment Alerts

Nautilus Biotechnology Upcoming and Recent Events

Nautilus Largest EPS Surprises

View All Earnings Estimates

Nautilus Biotechnology Thematic Classifications

Nautilus Stock Institutional Investors

Note, although Nautilus Biotechnology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nautilus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 353.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nautilus Biotechnology's market, we take the total number of its shares issued and multiply it by Nautilus Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Nautilus Profitablity

Management Efficiency

Nautilus Biotechnology has return on total asset (ROA) of (0.157) % which means that it has lost $0.157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2438) %, meaning that it created substantial loss on money invested by shareholders. Nautilus Biotechnology's management efficiency ratios could be used to measure how well Nautilus Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. Total Current Liabilities is likely to gain to about 9.6 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 235.6 M in 2024.

Technical Drivers

As of the 8th of May, Nautilus Biotechnology secures the Downside Deviation of 5.64, risk adjusted performance of 0.0199, and Mean Deviation of 3.68. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nautilus Biotechnology, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Nautilus Biotechnology, which can be compared to its peers in the industry. Please verify Nautilus Biotechnology jensen alpha and semi variance to decide if Nautilus Biotechnology is priced some-what accurately, providing market reflects its recent price of 2.66 per share. Please also check out Nautilus Biotechnology total risk alpha, which is currently at (0.43) to check the company can sustain itself at a future point.

Nautilus Biotechnology Price Movement Analysis

Nautilus Biotechnology Insider Trading Activities

Nautilus Biotechnology Predictive Daily Indicators

Nautilus Biotechnology Corporate Filings

Nautilus Biotechnology Forecast Models

Nautilus Biotechnology's time-series forecasting models are one of many Nautilus Biotechnology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nautilus Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nautilus Biotechnology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nautilus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nautilus Biotechnology. By using and applying Nautilus Stock analysis, traders can create a robust methodology for identifying Nautilus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nautilus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nautilus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Nautilus Biotechnology stock analysis indicators help investors evaluate how Nautilus Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nautilus Biotechnology shares will generate the highest return on investment. By understating and applying Nautilus Biotechnology stock analysis, traders can identify Nautilus Biotechnology position entry and exit signals to maximize returns.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nautilus Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.

Is Nautilus Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nautilus Biotechnology. If investors know Nautilus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nautilus Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Nautilus Biotechnology is measured differently than its book value, which is the value of Nautilus that is recorded on the company's balance sheet. Investors also form their own opinion of Nautilus Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Nautilus Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nautilus Biotechnology's market value can be influenced by many factors that don't directly affect Nautilus Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Nautilus Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nautilus Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nautilus Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.